

Curriculum Vitae



Prof. KHALED ABOUZID MOHAMED

e-mail: khaled.abouزيد@pharma.asu.edu.eg, abouزيد@yahoo.com

Links

Scopus H index = 28

Google Scholar H index = 30

<https://www.linkedin.com/in/khaled-abouزيد-97576139/>

<https://www.scopus.com/authid/detail.uri?authorId=8919613900>

https://www.researchgate.net/profile/Khaled_Abouزيد2/research

https://scholar.google.com.eg/citations?hl=en&user=mM7Ye38AAAAJ&view_op=list_works&sortby=pubdate

<https://publons.com/researcher/3005074/khaled-abouزيد/>

<http://staff.asu.edu.eg//index.php?id=pharma-151&action=publication>

<http://fop.usc.edu.eg/ar/dean/459.aspx>

<https://orcid.org/0000-0001-9851-5624>

Web of Science ResearcherID S-8284-2019

Summary of Qualifications

Educational experience:

Teaching organic and pharmaceutical chemistry for undergraduate and postgraduate students.

Research work:

Excellence in pharmaceutical, medicinal chemistry and drug discovery research

Administrative work:

-Manager of the quality assurance unit at the faculty of pharmacy, Ain Shams Univ. for three years.

- Executive manager for accreditation project CIQAAP at the Faculty of Pharmacy- Ain Shams University for 30 months.
- Vice Dean for students' affairs for 6 years
- Head of pharmaceutical chemistry department
- Acting dean of the Faculty of Pharmacy, University of Sadat City

Education

- 1995: Ph. D, Pharmaceutical Sciences (Organic Chemistry)
Faculty of Pharmacy, **Cairo University** and Pharmacy, **University of Connecticut, USA** with *2-years scientific mission from 1992-1994*
- 1990: M Sc. , Pharmaceutical Sciences (Organic Chemistry)
Faculty of Pharmacy, Organic Chem. Dept., Cairo University.
- 1985: B. Sc. , Pharmaceutical Sciences, Grade: Excellent with honor ,
Faculty of Pharmacy, Cairo University.

Professional Experience

1985 -1990:

Instructor of Pharmaceutical Organic Chemistry
Organic Chem. Dept., Faculty of Pharmacy
Cairo University, Cairo, EGYPT.

1990-1995

Assistant Lecturer of Pharmaceutical Organic Chemistry
Organic Chem. Dept., Faculty of Pharmacy, Cairo University, EGYPT.

1992-1994:

Member of Educational Mission & Researcher
In medicinal Chemistry Department, School of Pharmacy, University of Connecticut, USA under the supervision of Prof. Alexandros Makriyannis.

1995- 2001:

Lecturer of Organic Chemistry
Organic Chem. Dept., Faculty of Pharmacy, Cairo University, EGYPT

2001-2003:

Lecturer_at pharmaceutical chemistry department, Faculty of pharmacy, Ain Shams University

28/7/2003 to 16/8/2008 :

Associate Professor of Pharmaceutical Chemistry, Pharmaceutical Chem. Dept., Faculty of Pharmacy, Ain Shams University-Cairo- EGYPT

7/2005-10/2005 :

As post-doctoral scientific mission fellow to the Faculty of Biology and Pharmacy, Friedrich-Schiller-Universität Jena, Germany

16/8/2008 :

Professor at Pharmaceutical Chem. Dept., Faculty of Pharmacy, Ain Shams University

12/10/2008 to 4-11-2009 :

Head of Pharmaceutical Chemistry
Dept., Faculty of Pharmacy, Ain Shams University

5-11-2009-4-11-2015 :

vice dean of educational and students affairs, Faculty of Pharmacy, Ain Shams University

5-11-2015 -14-10-2018

Head of Pharmaceutical Chemistry, Dept, Faculty of Pharmacy, Ain Shams University

15-10-2018 till now

Acting Dean of the Faculty of Pharmacy, Sadat City University

Professional and Scientific Activities & Expertise

● **Teaching Experiences:**

- Lectured organic chemistry and pharmaceutical chemistry practical sessions for undergraduate pharmacy students (preparatory, first, second, third and fourth years) at the Universities of Cairo, Ain Shams, MIU, GUC.
- Lectured organic chemistry and pharmaceutical chemistry for undergraduate pharmacy students (preparatory, first, second, third and fourth years) in the Universities of Cairo, Ain Shams, MIU, GUC.
- Lectured advanced organic chemistry, drug design and pharmaceutical chemistry for postgraduate pharmacy students at Ain Shams University.
- Examiner of organic and pharmaceutical chemistry at Ain Shams University.
- Designed practical sessions and developed appropriate supplementary materials, including an electronic organic chemistry laboratory manual for the undergraduate students at GUC in Cairo.

● **Examination Control Experience**

- 2004 to 2008 : Head of the first year examination control at Faculty of Pharmacy- Ain Shams University.
- **External Appointments**
 - 2000/2001 Semesters: appointed to teach at Ain Shams University.
 - 2001/2002 & 2002/2003 appointed to teach organic chemistry at MIU.
 - 2006 to 2008 Appointed to teach pharmaceutical and organic chemistry at GUC.
 - 2/2008 Appointed to teach Organic Chemistry course at Al-Fateh University, Tripoli, Libya.
 - External Examiner of organic and pharmaceutical chemistry for undergraduates at the Universities of: Cairo, Alexandria, Mansoura, Helwan, Tanta, Zagazig, Assiut, Menya, Suez Canal, Azhar (Girls and Boys sections), 6th of October, MUST, Canadian Ahram and the Egyptian-Russian.
- **Training Courses:**
 - 8-19 February 1992: attended training Course for the Preparation of University Lecturer at the University of Cairo.
 - 8-10 May 2001: attended workshop of "Writing Research Projects" at Faculty of Nursing- Cairo University.
 - 2006: attended two workshops on "Interactive Teaching" King's College University of London- UK
 - 2007: "Preparation and Development of Chemistry Curricula" at King's College University of London- UK, through the Tempus project by Sekem Foundation for Development.
 - Starting from 2005: attended six courses for the development of capabilities of Ain Shams University staff members and leadership personnel.
 - 2012 one-week Workshop on "University Leadership and Management in an International Context" at the premises of "DAAD Cairo"
 - 2018 One-week Workshop about chemical safety and security by Sadia, USA, Hilton Zamalek
- **Research Projects:**
 - As a member of the research group working on "National Institute of Drug Abuse" Project (School of Pharmacy-University of Connecticut, CT, USA); achieved the synthesis of winning anandamides analogues in 1994
 - Statin nitrate hybrid compounds at the school of pharmacy, Jena, Germany 2005
 - Participated in a two-years project; "Synthesis of Egyptian Drug Used for Treatment of Hypertension", funded by Ain Shams University; 12/2001.

- PI of the project titled Design and synthesis of AMPK inhibitors to combat cancer (Funds 50,000 LE) from Ain Shams University since 2017
- Member of research team of two research projects at university of Sadat City

Membership of Professional Associations and Committees

-
- Member of the National committee for crystallography.
 - Member of the Egyptian Pharmaceutical Society since 1995.
 - Pharmacy ASU, Faculty council member
 - Member of Committee for Higher Postgraduate Studies.
 - Head of Student's Affair Committee.
 - Environment and Society Services Committee.
 - Member of Ain Shams Student's Affair Committee
 - Member of Permanent Committee for Student's Affairs, Ain Shams university
 - Moderator of quality assurance unit committee at Faculty of pharmacy ASU
 - Moderator of Alumini Association committee
 - Member of the national promotion committee for professors and assistant professors in medicinal and biochemistry, SCU, cycle 12 and 13. 14
 - Member of the promotion committee for professors and assistant professors in medicinal chemistry at Azhar university
 - Director of the promotion committee for professors and assistant professors in medicinal chemistry at NODCAR
 - Member of MASRI research center at the faculty of medicine ASU
 - Member of university of Sadat City Council since Oct 2018 till 2020

Activities in the Field of Quality Assurance Management

- Preparing the final report for the qualification project of accreditation for the Faculty of Pharmacy- Ain Shams University.
- Field visits for disseminating quality system for national academic reference standards (NARS) for the pharmacy sector in some of the Faculties of Pharmacy in Egypt.
- A member of the research team for the preparation of the "National Reference Standards for Pharmaceutical Education in Egypt". These reference standards have been accredited by the Pharmaceutical Education Sector Committee starting from the school year 2006/2007.
- Attended workshops and training courses in the quality assurance field for example:
 - Quality management center- Ain Shams University.
 - "Peer Reviewers - Faculty of Agriculture – Cairo University.

- "How to prepare study curricula description and designing, preparing and writing quality projects", at the Faculty of Pharmacy- Ain Shams University.
- Strategic planning at Faculty of Agriculture – Cairo University.
- Attended the International Conference for Quality Assurance, Cairo University, 15th April 2008.
- Management Positions Regarding Quality Assurance:
 - Executive Manager of the Accreditation Project "CIQAP" (10 Million LE) for upgrading the faculty from 3-2008-to 10-2010.
 - Manager of the Quality Assurance Unit- Faculty of Pharmacy- Ain Shams University from 3-2008 to 27-11-2011 which finally led to accreditation of the Faculty of Pharmacy Ain Shams University in 11 October 2011

Capacity building activity

- Establishment of Drug Design Laboratory- Faculty of Pharmacy- Ain Shams University.
- co-founder of Center of excellence in drug discovery at the faculty of pharmacy, Ain Shams university May 2013
- Committee principal for purchasing laboratory equipment for undergraduates and postgraduates Labs from CIQAP

Social Activities

- Head of Egyptian Postgraduate Students 'Association in Storrs, Connecticut, USA from 1993 to 1994.
- Head of the Student's Committee for Social Activities, Faculty of Pharmacy- Ain Shams University starting from 2004 to 2008.
- Consultant for Eva pharm for optimization of the synthesis of Active pharmaceutical ingredients (API)

Awards

- May 2008: The International Publication Awards from Ain Shams University, for international publication.
- Among the list of distinguished 2% international scientists published by Stamford University

Scientific Productivity

- Referee for international journals such as bioorganic medicinal chemistry, medicinal chemistry research, European journal of medicinal chemistry and arch der pharmazie.
- Reviewer at national STDF projects
- Reviewer at scientific research academy, prize sector
- Thesis Examiner:
External Examiner of PhD and Master theses in Cairo, Assuit, Alexandria, Azhar, Zagazig, Menia, Suez Canal, Helwan, GUC universities
- Thesis supervisions:
Supervised 110 Master and PhD students at Cairo, ASU, GUC Helwan, Damanhour, and Kanat Suez universities

International Scientific Collaboration

- **Joint supervision collaboration with the following Universities:**
 - The Ohio State University
 - The Michigan State University
 - The Georgia State University
 - University of Alberta, Canada
 - Joint research with Jena university and Heidelberg
-

Publications

List of Publication

1. "Synthesis of 1,4-Disubstituted Piperazines as Potential Antihypertensive Agents", K. A. M. Abou-Zeid, K. M. Youssef, F. M. Amine, S. Botros and Z. Isaa; *Egypt. J. Pharm. Sci.*, Vol. 30, No. 1-4, pp. 429-436, (1989).
2. "Synthesis and Antihypertensive Activity of 1,4-Disubstituted Piperazines", K. A. M. Abou-Zeid, K. M. Youssef, F. M. Amine and S. Botros; *Egypt. J. Pharm. Sci.*, Vol. 32, No. 1-2, pp. 165-174 (1991).
3. "6-[4-(Substituted-Amino)Phenyl]-4,5-Dihydropyridazin-3(2H)-ones as Cardiotonic Agents", K. A. M. Abou-Zeid, K. M. Youssef, M.A. Shaaban, F.A. El-Telbany and S.H. Al-Zanfaly; *Bull. Fac. Pharm. Cairo Univ.*, Vol. 33, pp. 9-11 (1995).
4. "Synthesis and Phosphodiesterase Inhibiting Activity of Some 6-Substituted-4,5-Dihydropyridazin-3(2H)-ones" K. A. M. Abou-Zeid, K. M. Youssef, M.A. Shaaban, F.A. El-Telbany and S.H. Al-Zanfaly; *Bull. Fac. Pharm. Cairo Univ.*, Vol. 33, pp. 25-28 (1995).
5. "Synthesis of Novel 4,5-Dihydropyridazin-3(2H)ones Derivatives with Benzoxazine and Benzoxazole Heterocycles at the 6- Position as Cardiotonic agents"; K. A. M. Abou-Zeid, K. M. Youssef, M.A. Shaaban, F.A. El-Telbany and S.H. Al-Zanfaly; *Egypt J. Pharm. Sci.*, 38, 303 (1997).
6. "Synthesis of 6-[4-(Substituted-amino)phenyl]-4,5-Dihydropyridazin-3(2H)ones as Potential positive Inotropic Agents"; K. A. M. Abou-Zeid, K. M. Youssef, M.A. Shaaban, F.A. El-Telbany and S.H. Al-Zanfaly, *Egypt J. Pharm. Sci.*, 38, 319 (1997).
7. "Head Group Analogs of Arachidonylethanolamide, the Endogenous Cannabinoid Ligand", A. D. Khanolkar, V. Abadji, S. Lin, W. A. G. Hill, G. Taha, K. Abouzid, Z. Meng, P. Fan and A. Makriyannis; *J. Med. Chem.*, 39, pp.4515-4519 (1996). <http://dx.doi.org/10.1021/jm960152y> ISI Impact Factor: 6.50
8. "Substrate Specificity And Stereoselectivity Of Rat Brain Microsomal Anandamide Amidohydrolase", Lang, W., C. Qin, S. Lin, A.D. Khanolkar, A. Goutopoulos, P. Fan, K. Abouzid, Z. Meng, D. Biegel, and A. Makriyannis; *J. Med. Chem.*, 42, pp. 896-902 (1999). ISI Impact Factor: 6.50
<http://dx.doi.org/10.1021/jm980461j>
9. "Synthesis and Evaluation for Potential Antihypertensive Activity of a Series of Substituted Imidazolinone Oximes and Cyclohexanespiro-8-imidazo[5,1-c]-1,2,4-oxdiazines" Mohamed Abdel Hamid Ismail, Khaled Abouzid, Awatef, E. Farag and Amani E. Khalifa; *Alex. J Pharm. Sci.*, 14(2), pp. 151-161 (2000).
10. Synthesis and Antihypertensive Activity of Novel benzimidazole, benzoxazole and benzothiazole derivatives Khaled Abouzid, Hanan Refaat, Maha Abdel Hakeem and Ashraf B. Abdel-Naim; *Bull. Fac. Pharm. Cairo Univ.*, 40(1), pp. 7-12 (2002).

11. "Synthesis of Certain Substituted Quinoxalines as Antimicrobial Agents (Part I)", Mohga M. Badran, Khaled A. M. Abouzid and M. H. M. Hussein; *Az. J. Pharm. Sci.*, 30, 57 (2002).
12. "Synthesis of Certain Thienopyrimidine Derivatives as Antimicrobial Agents", A. A. Mouneer, Khaled A. M. Abouzid and M. M. Said; *Az. J. Pharm. Sci.*, 30, 150 (2002).
13. "Synthesis of Certain 5,6,7,8-tetrahydrobenzo[b] thienopyrimidines Fused with Various Heterocyclic Ring Systems as Potential Antihypertensive Agents" Mohamed Abdel Hamid Ismail, Mohammed Nabil Y. Aboul-Einein, Khaled Abouzid, Sahar Kandil; *Alex. J Pharm. Sci.*, 15(2), 143 (2002).
14. "Synthesis and Antimicrobial Activity of Certain Substituted Quinoxalines (Part II) "; Mohga M. Badran, Khaled A. M. Abouzid and M. H. M. Hussein; *Arch. Pharm. Res.*, 26, 2, pp. 107-113 (2003) <http://apr.psk.or.kr>
15. "Synthesis and Antiinflammatory Activity of Novel Indazolones", Khaled A. M. Abouzid and H. S. El-Abhar; *Arch. Pharm. Res.*, 26, 1, pp. 1-8 (2003). (Springer) <http://apr.psk.or.kr>
16. "Synthesis and Biological Evaluation of New Thiazolopyrimidines", Makarem Said, Khaled A. M. Abouzid, Ashraf Mouneer; *Arch. Pharm. Res.*, 27, pp. 471-477 (2004). (Springer) <http://apr.psk.or.kr>
17. "Antipyretic, Antinoceptive and Anti-inflammatory Activity of Certain oxbutanoic Acid Derivatives", Khaled A.M. Abouzid, Khairia M Youssef, Amany A. E. Ahmed and Hanna Hussain Al-Zuhair; *Med. Chem. Res.*, 14:1, pp. 26-39 (2005).
<http://dx.doi.org/10.1007/s00044-004-0123-6>
18. "Ligand Design and Synthesis of New Imidazo[5,1-b]quinazoline Derivatives as α_1 -Adrenoceptor Agonists and Antagonists"; Mohamed A. H. Ismail, Mohamed N. Y. Aboul-Enein, Khaled A. M. Abouzid and Rabah A. T. Serya; *Journal of Bioorganic & Medicinal Chemistry*, 14, pp. 898-910 (2006). (Elsevier) <http://dx.doi.org/10.1016/j.bmc.2005.07.037>
19. "Design and Synthesis of New Tetrazolyl and Carboxy-biphenyl methyl-quinazolin-4-one Derivatives as Angiotensin II AT1 Receptor Antagonists", Mohamed A. H. Ismail, Stewart Baker, Dalal A. Abou El Ella, Khaled Abouzid, Rabab A Toubar and Matthew H Todd; *J. Med. Chem.*, 49, pp. 1526-1535 (2006). <http://dx.doi.org/10.1021/jm050232e> ISI Impact Factor: 6.50
20. "Design, Synthesis and Antihypertensive Activity of Certain Pyrazolopyrimidines with Arylpiperazine Side Chains", Khaled Abouzid, Azza Taher, Hanan H. Kadry; *Bull. Fac. Pharm. Cairo Univ.*, 45(2), pp. 87-97 (2007).
21. "Design, Synthesis and Blood Pressure Lowering Activity of Certain Tetrahydrobenzo[b]thiophene Derivatives with Arylpiperazinyl Side Chains", Khaled Abouzid, Azza Taher, Mona M. Kamel; *Bull. Fac. Pharm. Cairo Univ.*, 45(2), pp. 75-85 (2007).
22. "6-Aryl-4-oxohexanoic Acids: Synthesis, Effects on Eicosanoid Biosynthesis, and Anti-inflammatory in vivo -Activities", Khaled Abouzid, Petra Frohberg, Jochen Lehmann, and Michael Decker; *Medicinal Chemistry*, 3, pp. 433-438 (2007) <http://dx.doi.org/10.2174/157340607781745393>

23. "Design, Synthesis and *in vitro* Antitumor Activity of 4-Aminoquinoline and 4-Aminoquinazoline Derivatives Targeting EGFR Tyrosine Kinase", Khaled Abouzid and Samia Shouman; *Bioorganic & Medicinal Chemistry* 16, 7543-7551 (2008) (Elsevier)
<http://dx.doi.org/10.1016/j.bmc.2008.07.038>
24. "Novel Anti-Inflammatory Agents Based on Pyridazinone Scaffold; Design, Synthesis and *in vivo* Activity", Khaled Abouzid and Salma A. Bekhit; *Bioorganic & Medicinal Chemistry*, 6, 5547-5556 (2008) (Elsevier).
<http://dx.doi.org/10.1016/j.bmc.2008.04.007>
25. "Pyridazinone Derivatives; Design, Synthesis and *in vitro* Vasorelaxant Activity", Khaled Abouzid, Maha Abdel Hakeem and Omnya Khalil, Yosria Maklad; *Bioorganic & Medicinal Chemistry*, 16(1), pp. 382-389 (2008). <http://dx.doi.org/10.1016/j.bmc.2007.09.031>
26. Design, synthesis and anti-inflammatory activity of 3-arylethenyl-6-substituted-pyridazines: Khaled A. M. Abouzid, Nadia A. Khalil, Eman M. Ahmed, Hekmat A. Abd El-Latif, *Bull. Fac. Pharm. Cairo Univ.*, 46(3), pp. 87-97 (2008).
27. "Lonazolac Analogues: Molecular Modeling, Synthesis and *in vivo* Anti-inflammatory Activity" Mohamed A. H. Ismail, Jochen Lehmann, Dalal A. Abou El Ella, Amgad Albohy and Khaled A. M. Abouzid. *Med. Chem. Res* (Springer) 18,725-744 (2009).
[DOI 10.1007/s00044-009-9163-2](https://doi.org/10.1007/s00044-009-9163-2)
28. "ACE inhibitors hypothesis generation for selective design, synthesis and biological evaluation of 3-mercapto-2-methyl propanoylpyrrolidine-3-imine derivatives as antihypertensive agents". Mohamed A. H. Ismail, Mohamed N. Y. Aboul-Enein, Khaled A. M. Abouzid Dalal A. Abou El Ella and Naser Saad *Bioorganic & Medicinal Chemistry*, 17, 3739-3746 (2009). (Elsevier)
[DOI: 10.1016/j.bmc.2009.03.008](https://doi.org/10.1016/j.bmc.2009.03.008)
29. Novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors" Ashraf H. Abadi, Tamer M. Ibrahim, Khaled M. Abouzid, Jochen Lehmann, Heather N, Tinsley, Bernard D. Gary, Gary A. Piazza *Bioorganic & Medicinal Chemistry* 17 (2009) 5974-5982. (Elsevier)
[doi:10.1016/j.bmc.2009.06.06](https://doi.org/10.1016/j.bmc.2009.06.06)
30. Molecular Modeling Design, Synthesis and Biological Evaluation of New Imidazoline Derivatives Linked as $\alpha 1$ -AR Antagonists and AngII Receptor Antagonists, Mohamed A. H. Ismail, Dalal A. R. Abou El Ella, Khaled A. M. Abouzid and Deena S. M. Lasheen *Jordan Journal of Chemistry* 4 (4), (2009), 329-347
31. Structure-Based Molecular Design, Synthesis and *in-vivo* Anti-inflammatory Activity of Pyridazinone Derivatives as Non-Classic COX-2 Inhibitors" Khaled A. M. Abouzid, Nadia A. Khalil, Eman M. Ahmed, Hekmat A. Abd El-Latif and Moustafa E. El-Araby *Med. Chem. Res* 19: 629-642 (2010). (Springer)
[DOI: 10.1007/s00044-009-9218-4](https://doi.org/10.1007/s00044-009-9218-4)

32. Organic synthesis and biological evaluation of novel (3+1) mixed ligands of technetium-99m Gabapentin as receptor imaging agents. A. M. Ami, K. Abou zid, N. A. Bayoumi and M. Abd El-hamid. *J Radioanal Nucl Chem* (2010) 283:55–62
DOI 10.1007/s10967-009-0059-x
33. Nitrat-Statin-Hybride eine neue Option zur Therapie der Alzheimer'schen Krankheit Lengfelder Claudia; Traber Heidi; Roegler Carolin, Khaled abuzid and Jochen Lehmann; Herz supplement (Munchen. Print) 35 (2010) 12-17.
34. Computer based drug design, synthesis and biological evaluation of new pyrimidinone derivatives linked to arylpiperazine and 2'-carbomethoxy-biphenylmethyl moieties as α_1 -adrenoceptor antagonists and angiotensin II AT1 receptor antagonists . Ismail, M. A. H.; Abou El Ella, D. A.; Abouzid, K. A. M.; Al-Ansary, G. H. A. *Pharmazie* (2010), 65(11), 794-800.
doi: 10.1691/ph.2010.9732
35. Synthesis, Binding Studies and Molecular Modeling of Novel Cannabinoid Receptor Ligands Noha A. Osman, Amr H. Mahmoud, Marco Allar, Raimund Niess, Khaled A. Abouzid, Vincenzo Di Marzo, Ashraf H. Abadi *Bioorganic & Medicinal Chemistry*, 18 (2010) 8463–8477. (Elsevier) doi:10.1016/j.bmc.2010.10.05
36. Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as alfa1-adrenoreceptor antagonists; Sahar Mahmoud Abou-Seri, Khaled Abouzid and Dalal A. Abou El Ella *European Journal of Medicinal Chemistry* 46 (2) 647-658 (2011) (Elsevier)
doi10.1016/j.ejmech.2010.11.045
37. Baclofen ester and carbamate prodrug candidates: A simultaneous chromatographic assay, resolution optimized with DryLab: (Rasha Hanafia, Salwa Mosada, Khaled Abouzid, Raimund Nieß, Hilde Spahn-Langguth. *Journal of Pharmaceutical and Biomedical Analysis* 56 (2011) 569– 576 (Elsevier)
doi: 10.1016/j.jpba.2011.06.023
38. Synthesis and evaluation of antiproliferative activity of 1,4-disubstituted phthalazines, Khaled A. M. Abouzid, Nadia A. Khalil and Eman M. Ahmed. *Medicinal Chemistry Research* 21:3288–3293 (2012) (Springer)
DOI 10.1007/s00044-011-9874-z
39. Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives K. A. M. Abouzid, N. A. Khalil, E. M. Ahmed, A. Esmat and A. M. Al-Abd, *Medicinal Chemistry Research* (2012) 21:3581-3590 (*Springer*)
DOI 10.1007/s00044-011-9895-7
40. Preparation of ^{99m}Tc -Ceftazidime as a Model of Infection Imaging Agent M. A Motaleb, A. A. El-Mohty, M. A. El Garhy, Mohamed A H Ismail, Khaled A. M. Abouzid and T M. Sakr, *Arab Journal of Nuclear Sciences and Applications*, 44 (3), 57(2011)
41. Labeling and Biological Evaluation of ^{99m}Tc -Cefotaxime for infective Inflammation Diagnosis, M. A Motaleb, A. A. El-Mohty, M. A. El Garhy, Mohamed A H Ismail,

Khaled A. M. Abouzid and T M. Sakr, Arab Journal of Nuclear Sciences and Applications, 44, 67 (2011)

42. Synthesis and Binding Study of Certain 6-Arylalkanamides as Molecular Probes for Cannabinoid Receptor Subtypes Azza T. Taher, Hanan H. Kadry, Marco Allarà, Vincenzo Di Marzo, Ashraf H. Abadi and Khaled A Abouzid Journal of Enzyme Inhibition and Medicinal Chemistry 2013 Jun;28(3):436-9 *Informa*
DOI: 10.3109/14756366.2011.645241
43. Optimization of Benzoisothiazole dioxide inhibitory activity of the NS5B polymerase of HCV genotype 4 using ligand-steered homological modeling, reaction-driven scaffold-hopping and E-novo workflow Amr Hamed Mahmoud, Khaled Abouzid Mohamed, Dalal Abd El Rahman Abou El Ella, Mohamed Abdel Hamid Ismail Bioinformation 7(6): 328-333 (2011)
44. Integrated structure-based activity prediction model of benzothiadiazines against various genotypes of HCV NS5b polymerase (1a,1b and 4) and its application in the discovery of new derivatives, Mohamed A.H. Ismail Dalal A. Abou El Ella, Khaled A.M. Abouzid, Amr H. Mahmoud, Bioorganic & Medicinal Chemistry 20 (2012) 2455-2478
doi:10.1016/j.bmc.2012.01.03
45. A Highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues, Amr H. Mahmoud, Dalal A. Abou El Ella, Mohamed A.H. Ismail, Khaled A.M. Abouzid, European Journal of Medicinal Chemistry, 57, 2012, 468-482.
doi:10.1016/j.ejmech.2012.04.016
46. Synthesis and Anti-proliferative Activity of Substituted-Anilinoquinazolines and Its Relation to EGFR Inhibition, D. A. A. El Ella 1 , K. A. Saleh , M. Hassan , N. Hamdy , M. E. El-Araby , K. A. M Abouzid Arzneimittel-forschung, ; 62(08): 360-366 (2012)
http://dx.doi.org/ 10.1055/s-0032-1312601
47. Novel 2-thiopyrimidine derivatives as CDK2 inhibitors: molecular modeling, synthesis, and anti-tumor activity evaluation, Omar Abd El-Fattah M. Fathalla, Mohamed A. H. Ismail, Manal M. Anwar, Khaled A. M. Abouzid, Aisha A. K. Ramadan, Medicinal Chemistry Research, 36(1) 41-5 April (2012).
DOI 10.1007/s00044-012-0051-9
48. "Substituted phthalazines and Phthalazinones: Synthesis, Characterization and β -Adrenergic Blocking Activity. Khaled A. M. Abouzid, Nadia Khalil and Eman M. Ahmed, Medicinal Chemistry Research, 22, Issue 3 (2013), 1057-1064
DOI 10.1007/s00044-012-0099-6
49. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors, Mohamed Saad Abdullah Elsayed, Moustafa El-Sayed El-Araby, Rabah Ahmed Taha Serya and Khaled Abouzid Arzneimittel-forschung 2012; 62: 554-560
DOI:10.1055/s-0032-1323759

50. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors Mohamed S.A Elsayed, Moustafa E El-Araby, Rabah A.T. Serya, Ahmed H. El-Khatib, Michael W. Linscheid and Khaled A. M Abouzid *European Journal of Medicinal Chemistry* vol 61, 122-131 March (2013)
[doi:10.1016/j.ejmech.2012.09.039](https://doi.org/10.1016/j.ejmech.2012.09.039).
51. Design, Synthesis and in vitro Anti-proliferative Activity of 4,6-Quinazolinediamines as Potent EGFR-TK Inhibitors Samar Mowafy, Nahla. A. Farag, Khaled A. M. Abouzid. *European Journal of Medicinal Chemistry*, vol 61, March 2013, 132-145 (2013).
[10.1016/j.ejmech.2012.10.017](https://doi.org/10.1016/j.ejmech.2012.10.017)
52. Ligand Design, Synthesis and Biological Anti-HCV Evaluations for Genotypes 1b & 4a of Certain 4-{3- & 4-[3-(3,5-Dibromo-4-hydroxyphenyl) propylamino] phenyl} butyric acids and 3-(3,5-Dibromo-4-hydroxyphenyl)-propylamino-acetamidobenzoic Acid Esters. Mohamed A. H. Ismail, **Khaled A. M. Abouzid**, Naser Saad and Eman M Elawady Dokla. *J Enzyme Inhib Med Chem*. 2013 Dec; 28(6):1274-90.. **ISI Impact Factor: 3.50**
[DOI:10.3109/14756366.2012.733384](https://doi.org/10.3109/14756366.2012.733384)
53. 3-[(6-Arylamino)pyridazinylamino]benzoic Acids: Design, Synthesis and in vitro Evaluation of Anticancer Activity **Khaled. A.M Abouzid**, Nadia A. Khalil, Eman M. Ahmed, and Khaled Omar Mohamed. *Arch. Pharm. Res.* (Springer) **36:41–50 (2013)**
<http://apr.psk.or.kr>
54. Design, synthesis and virtual screening of certain 2-pyrazolin-5-one and pyrazolidine-3, 5-dione derivatives as potential ppar agonists Mohamed A. H. Ismail, Dalal A. Abou El Ella, **Khaled A. M. Abouzid**, and Maiy Jaballah *IJPSR*, 2012; Vol. 3(10): 3746-3757.
55. Molecular Design, Synthesis and Cell Based HCV Replicon Assay of Novel Benzoxazole Derivatives Mohamed A. H. Ismail, Mai Adel, Nasser S. M. Ismail and **Khaled A. M. Abouzid**. *Drug Research*. 2013; **63: 109–120**
[DOI http://dx.doi.org/10.1055/s-0032-1331765](http://dx.doi.org/10.1055/s-0032-1331765).
56. Synthesis and biological evaluation of new heteroaryl carboxylic acid derivatives as anti-inflammatory-analgesic agents. **Khaled. A.M Abouzid**, Nadia A. Khalil, E. M. Ahmed, and Sawsan A. Zaitone. *Chemical Pharmaceutical Bulletin Japan*. **61 (2) 222-228 (2013)**.
57. Applying ligands profiling using multiple extended electron distribution based field templates and Feature trees similarity searching in the discovery of new generation of urea-based antineoplastic kinase inhibitors Eman M. Dokla, Amr H. Mahmoud, Mohamed S. A. Elsayed, Ahmed H. El-Khatib, Michael W. Linscheid, Khaled A. Abouzid *PLOS ONE*, 2012 Vol 7 (11) e49284. www.plosone.org
58. Induced fit docking, molecular dynamic simulation and QM/MM scoring for some new anti-HER2 compounds: Marawan Ahmed, Maiada M. Sadek, Rabah A. Serrya, Abdel-Hamid N. Kafafy, **Khaled A. Abouzid** and Feng Wang, *Journal of Molecular Graphics and Modelling*. **40, 91-98, (2013)**.
[doi:10.1016/j.jmgm.2012.12.001](https://doi.org/10.1016/j.jmgm.2012.12.001)

59. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents Maiada M. Sadek Rabah A. Serrya, Abdel-Hamid N. Kafafy, Marawan Ahmed, Feng Wang and **Khaled A. M. Abouzid** *J Enzyme Inhib Med Chem.* 2014 Apr; 29(2) :215-22.. **ISI Impact Factor: 3.50**
DOI: 10.3109/14756366.2013.765417
60. Analogs Design, Synthesis and Biological Evaluation of Peptidomimetics with Potential Anti-HCV Activity Deena S. Lasheen, Mohamed A. H. Ismail, Dalal A. Abou El Ella, Nasser S. M. Ismail, Sameh Eid, Susan Vleck, Jeffrey S. Glenn , Andrew G. Watts, **Khaled A. M. Abouzid.** *Bioorganic Medicinal Chemistry.* April (21) 2612-2755 2013.
DOI: 10.1016/j.bmc.2013.03.017
61. In Silico Design, Extended Molecular Dynamic Simulations and Binding Energy Calculations for a New Series of Dually Acting Inhibitors against EGFR and HER2 Marawan Ahmed, Maiada M. Sadek, **Khaled A. Abouzid,** Feng Wang *Journal of Molecular Graphics and Modelling,* July (44), 220-231, 2013.
<http://dx.doi.org/10.1016/j.jmgm.2013.06.004>
62. Molecular Design and Synthesis of HCV Inhibitors Based on Thiazolone Scaffold Ghada. H. Al-Ansary, Mohamed. A.H. Ismail, Dalal. A. Abou El Ella, Sameh Eid, **Khaled. A.M. Abouzid.** *European Journal of Medicinal Chemistry* October (68) 19-32, 2013 **ISI Impact Factor: 4.50**
<http://dx.doi.org/10.1016/j.ejmech.2013.07.006>
63. Molecular design and synthesis of 1,4-disubstituted piperazines as α 1-adrenergic receptor blockers.; Dalal A Abou El-Ella, Mohammed M Hussein, Rabah A T Serya, Rana M Abdel Naby, Ahmed M Al-Abd, Dalia O Saleh, Wafaa I El-Eraky, **Khaled A M Abouzid;** *Bioorganic Chemistry* 54, June, 21-30 (2014)
64. Molecular Modelling and Synthesis of Quinazoline-Based Compounds as Potential Antiproliferative Agents: Asmaa Said Ali Yassen, Hosam Eldin Abd Elhamed Ahmed Elshihawy, Mohamed Mokhtar Amin Said, **Khaled Abouzid Mohamed Abouzid** *Chemical & Pharmaceutical Bulletin, jpn* 05/2014; 62(5).
65. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold Mai I. Shahin, Dalal A. Abou El Ella, Nasser S.M. Ismail, **Khaled A.M. Abouzid** *Bioorganic Chemistry* 56, 16-26 (2014). Impact factor 2.1
<http://dx.doi.org/10.1016/j.bioorg.2014.05.010>
66. The importance of p38 inhibitors as chemotherapeutic agents. Abdel Nbs, Khaled AA, Maged KGM, Atef GH. *International Journal of Pharmaceutical Research and Bio-Science,* 06/2014; 3((3)):20-55. Impact Factor 1.862
67. Naphtahlene and 2,3-dihydrobenzo[b][1,4]dioxin Derivatives With Extended Side Chains as New Scaffolds of CB2 Selective Ligands, Ashraf H. Abadi, Noha Osman, Amr Mahmoud, Christian Klein, Vincenzo Di Marzo, Khaled A. M. Abouzid and Marco Allara. *Med Chem Comm* 5 (10), 1571-1576 31 Jul 2014. Impact factor 2.72
68. Design, synthesis, and antihypertensive evaluation of 2'-tetrazolyl and 2'-carboxy-biphenylmethyl-pyrrolidine scaffolds substituted at their N1, C3, and C4 positions as potential angiotensin II AT1 receptor antagonists. Mohamed A. H. Ismail, Mohamed

Nabil Aboul-Enein, Aida Abd ElSatar El-Azzouny, Khaled A. M. Abouzid, Nasser S. M. Ismail *Medicinal Chemistry Research* published online 16 July 2014

69. Design, synthesis, 3D Pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as cytotoxic agents, Mona M. Abdel-Atty, Nahla A. Farag, Shaymaa E.Kassab, Rabah A. T. Serya and Khaled A. Abouzid, *Bioorganic Chemistry* (57) 65–82 (2014) 24 Aug (2014). Impact factor 2.1
70. Synthesis and cytotoxicity studies of some new amino isoquinolin-5,8-dione and quinolin-5,8-dione derivatives, Ahmed B Abelwahab, Mohamed Shaaban, Mohamed A H Ismail, Khaled A M Abouzid and Atef G Hanna; *Indian Journal of Chemistry*, Vol 52B, 1098-1109 (2014)
71. Molecular modeling design, synthesis, and anti-hyperglycemic evaluation of certain 5-(aryl-alkoxy-benzylidene)-imidazolidine-2,4-dione derivatives as potential PPAR γ agonists, Mohamed A. H. Ismail, Dalal A. Abou El Ella, Khaled A. M. Abouzid, Nermin Samir Abdou and Antoon Lahham, *Medicinal Chemistry Research*, 24 (5), 2115-2126 October 2014, Impact factor 1.6
72. Newly designed and synthesized curcumin analogs with in vitro cytotoxicity and tubulin polymerization activity Iten M. Fawzy, Khairia M. Youssef, Nasser S. M. Ismail, J. Gullbo and Khaled A. M. Abouzid, *Chemical biology and drug design* July. 2015 Dec;86(6):1518-1527. doi: 10.1111/cbdd.12621, Impact factor 2.47
73. Discovery of novel tricyclic pyrido[3,0 :4,5]thieno[3,2-d]pyrimidin-4- amine derivatives as VEGFR-2 inhibitors. Yasmine M. Abdel Aziz , Mohamed M. Said , Hosam A. El Shihawy , Khaled A.M. Abouzid. *Bioorganic Chemistry* 60 (2015) 1–12 Impact factor 2.1.
74. Synthesis and Evaluation of 5-Chloro-2-Methoxy-N-(4-Sulphamoylphenyl) Benzamide Derivatives as Anti-cancer Agents, Ahmed M Abdelaziz, Mingfeng Yu1 , Peng Li , Longjin Zhong , Abdel Nasser B Singab , Atef G Hanna2 , Khaled A Abouzid , Maged KG Mekhael and Shudong Wang, *Med Chem* 2015, 5:6.<http://dx.doi.org/10.4172/2161-0444.1000272>
75. Synthesis and in vitro antiproliferative activity of novel pyrazolo[3,4-d]pyrimidine Derivatives" Nermin S. Abdou, Rabah A.T. Serya,, A. Esmat , M.F. Tolba, Nasser S.M. Ismail, and Khaled A. M. Abouzid. . *Med. Chem. Commun.*, 2015, 6, 1518-1534. DOI: [10.1039/c5md00127g](https://doi.org/10.1039/c5md00127g) Impact factor 2.49
76. Discovery of novel peptidomimetics as irreversible CHIKV nsP2 protease inhibitors using quantum mechanical based ligand descriptors. Eman M.El-labbad, Mohammed A. H. Ismail, Dalal A. Abou El Ella, Marawan Ahmed, Feng Wang, Khaled Barakat, and Khaled A. M. Abouzid. *Chemical Biology and Drug Design*, 86: 1518–1527 (2015) Impact factor 2.47
77. Targeting apoptotic machinery as approach for anticancer therapy: Smac mimetics as anticancer agents, Nevine M.Y. Elsayed, Dalal A. Abou El Ella, Rabah A.T. Serya, Khaled A.M. Abouzid. *Future Journal of Pharmaceutical Sciences*, Volume 1, Issue 1, June 2015, Pages 16-21

78. Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators Eman M. E. Dokla, Chun-Sheng Fang, Po-Ting Lai, Dr. Samuel K. Kulp, Dr. Rabah A. T. Serya, Dr. Nasser S. M. Ismail, Prof. Khaled A. M. Abouzid and Prof. Ching-Shih Chen. *Chem Med Chem* 9 SEP, 10, 1915 – 1923. 2015. DOI: [10.1002/cmcd.201500371](https://doi.org/10.1002/cmcd.201500371)
79. Discovery of potent anti-proliferative agents targeting EGFR tyrosine kinase based on pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine scaffold, Yasmine Mohamed Abdel Aziz, Mohamed Mokhtar Saida, Hosam Ahmed El Shihawy, Mai Fathy Tolba and Khaled Abouzid Mohamed Abouzid, *Chem. Pharm. Bull.* 63, 1015–1028 (2015)
80. Design, synthesis and biological evaluation of Novel Curcumin Analogs with anticipated anticancer activity, Iten M. Fawzy , Khairia M. Youssef , Nasser S.M. Ismail , J. Gullbo , Khaled A.M. Abouzid *Future Journal of Pharmaceutical Sciences* Volume 1, Issue 1, June 2015, Pages 22-31
81. Radioiodination and biological evaluation of Cladribine as potential agent for tumor imaging and therapy Noha Anwer Bayoumi · Abeer M. Amin · Nasser S. M. Ismail · Khaled A. M. Abouzid · Mohamed T. El-Kolaly *Radiochimica Acta* · October, 103 (11), 777-787 DOI: [10.1515/ract-2014-2357](https://doi.org/10.1515/ract-2014-2357)
82. Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents Eman Z. Elrazaz, Rabah A.T. Serya, Nasser S.M. Ismail, Dalal A. Abou El Ella, Khaled A.M. Abouzid, *Future Journal of Pharmaceutical Sciences* Volume 1, Issue 2, December 2015, Pages 33-41
83. Furo[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents, Marwa A. Aziz, Rabah A.T. Serya, Deena S. Lasheen, Khaled A.M. Abouzid, *Future Journal of Pharmaceutical Sciences*, , Volume 2, Issue 1, June 2016, Pages 1-8
84. Design, synthesis and biological evaluation of indazole-pyrimidine based derivatives as anticancer agents with antiangiogenic and antiproliferative activity. Nevine M. Y. Elsayed, Dalal A. Abou El Ella Rabah A. T. Serya, Mai F. Tolbab, Raed Shalaby and Khaled A. M. Abouzid, *Med. Chem. Commun* 9 Feb 2016, 7, 881-889,
85. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidine Scaffolds as Cancer Targeting Agents Marwa A. Aziz, Rabah A. T. Serya, Deena S. Lasheen, Amal Kamal Abdel-Aziz, Ahmed Esmat, Ahmed M. Mansour, Abdel Nasser B. Singab and Khaled A. M. Abouzid published online in Nature/Scientific Reports 15 April 2016 *Scientific Reports* 6, Article number: 24460 (2016); DOI: [10.1038/srep24460](https://doi.org/10.1038/srep24460) Impact factor 5.58
86. Quinoxaline Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity Aliya M. S El Newahie, Nasser S.M. Ismail , Dalal A.Abou El Ella and Khaled A.M. Abouzid · *Arch. Pharm. Chem. Life Sci.* 2016, 349, 309–326 9 APR 2016, ISI impact factor: 1.9
DOI: [10.1002/ardp.201500468](https://doi.org/10.1002/ardp.201500468)
87. Covalent EGFR Inhibitors; Binding Mechanisms, Synthetic Approaches and Clinical Profiles" to the Archiv der Pharmazie. Monia Hossam, Deena S. Lasheen and Khaled

88. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline. Samar Mowafy, A. Galanis Zainab M Doctor, Raymond M. Paranal, Deena Lasheen, Nahla Farag Pasi A. Jänne and Khaled Abouzid *Bioorganic & Medicinal Chemistry* Volume 24, Issue 16, 15 August 2016, Pages 3501-3512
Impact Factor: 2.79 · DOI: [10.1016/j.bmc.2016.05.063](https://doi.org/10.1016/j.bmc.2016.05.063).
89. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality Noha A. Osman, Alessia Ligresti, Christian D. Klein, Marco Allarà, Alessandro Rabbito, Vincenzo Di Marzo, Khaled A. Abouzid,, Ashraf H. Abadi *European Journal of Medicinal Chemistry* , (2016)· 122, 619-634 **ISI Impact Factor: 4.50** DOI: [10.1016/j.ejmech.2016.07.012](https://doi.org/10.1016/j.ejmech.2016.07.012)
90. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors Soha R. Abd El Hadi, Deena S. Lasheen_, Mahmoud A. Hassan, and Khaled A. M. Abouzid *Arch. Pharm. Chem. Life Sci.* 2016, 349, 1–21
<http://dx.doi.org/10.1016/j.bmc.2016.05.063>
91. Pyridazine based scaffolds as privileged structures in anti-cancer therapy, Maiy Y.Jaballah*, Rabah A.T. Serya, Khaled A.M. Abouzid. *Drug Research* (Stuttg) (2017) 67, 138-148, DOI <http://dx.doi.org/10.1055/s-0042-119992>
92. Click and Release: SO₂ Prodrugs with Tunable Release Rates Xing-yue Ji , Eman M. El-labbad, Eman M. El-labbad,, Deena Lasheen, , Rabah Serya, Khaled Abouzid, , Binghe Wang, *Organic Letters* · (2017) 19 (4), 818–821 **ISI Impact Factor: 6.60**
DOI: [10.1021/acs.orglett.6b03805](https://doi.org/10.1021/acs.orglett.6b03805)
93. Pyrazolo[1,5-a][1,3,5]triazine based scaffold as purine analogues with diverse biological activity, Mazin A. A. Najm, Rabah A. T. Serya and Khaled A. M. Abouzid *Journal of American Science* 2017;13(3), 76-95
<http://doi:10.7537/marsjas130317.08>
94. An overview on the prospective CDKs inhibitors as anti-cancer drugs: Review article, Khulood H. Oudah, Nermin S. Abdou, Rabah A. T. Serya and Khaled A. M. Abouzid, *Journal of American Science* 2017;13(4) 6-23
<http://doi:10.7537/marsjas130417.02>
95. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities, Khaled M. Abouzid, Ghada H. Al-Ansary, Abeer M. El-Naggar ,*European Journal of Medicinal Chemistry*, (2017) 134, 357–365 **ISI Impact Factor: 4.50**

<http://doi.org/10.1016/j.ejmech.2017.04.024>

96. Synthesis, ADMET properties, and biological evaluation of benzothiazole compounds targeting CXCR2 Wesam E. Mehanna, Tiangong Lu, Bikash Debnath, Deena S. Lasheen, Rabah A. T. Serya, Khaled A. Abouzid, and Nouri Neamati *Chem Med Chem* 12, (13) 1045-1054, 2017 DOI: [10.1002/cmdc.201700229](https://doi.org/10.1002/cmdc.201700229) **Impact Factor: 3.30**
97. **How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors** Sandra N. Milik, Deena S. Lasheen, Rabah A. T. Serya, Khaled A. Abouzid *European Journal of Medicinal Chemistry* 142, 131-151, 2017 doi.org/10.1016/j.ejmech.2017.07.023 **Impact Factor: 4.80**
98. **Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities** Amna Ghith , Nasser S.M. Ismail , Khairia Youssef , and Khaled A.M. Abouzid *Arch. Pharm. Chem. Life Sci.* 2017, 350, e1700242 DOI [10.1002/ardp.201700242](https://doi.org/10.1002/ardp.201700242). **Impact Factor 2.1**
99. **Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity** Monia Hossam, Deena S. Lasheen , Nasser S.M. Ismail, Ahmed Esmat, Ahmed M. Mansour, Abdel Nasser B. Singab, Khaled A.M. Abouzid, *European Journal of Medicinal Chemistry*, 144, 330-348, 2018 <https://doi.org/10.1016/j.ejmech.2017.12.022> **Impact Factor: 4.80**
100. Design, synthesis, molecular docking study, and biological evaluation of salicylaldimine derivatives as potential histone deacetylases inhibitors (HDACi) and anticancer agents Heba M. Hesham, Deena S. Lasheen, Khaled A. Abouzid Archives of Pharmaceutical Sciences Ain Shams University 2018; Vol. 2(1):1-15 DOI: [10.21608/APS.2018.18729](https://doi.org/10.21608/APS.2018.18729)
101. **Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy**, Mai Adel, Rabah A. T. Serya, Deena S. Lasheen, Khaled A. M. Abouzid, Drug research (Stuttg) , online 16.01.2018 DOI: [10.1055/s-0044-101256](https://doi.org/10.1055/s-0044-101256)
102. **Design, synthesis and 3D QSAR based Pharmacophore Study of Novel Imatinib Analogs as Antitumor-Apoptotic Agents** Iten M. Fawzy, Khairia M. Youssef, Deena S. Lasheen, Nasser S. M. Ismail and Khaled A. M. Abouzid. Future Medicinal Chemistry online May 23th 2018 impact factor 3.55
103. **Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens.** Moustafa ElAwamy , Haroon Mohammad , Abdelrahman Hussien, Nader S. Abutaleb, Mohamed Hagra. Rabah A.T. Serya., Azza T. Taher, Khaled AM Abouzid, Mohamed N. Seleem , and Abdelrahman S. Mayhoub **European Journal of Medicinal Chemistry** 152 (2018) 318e328 **Impact Factor: 4.50**
<https://doi.org/10.1016/j.ejmech.2018.04.049>
104. **Chimeric HDAC inhibitors comprehensive review on the HDAC based strategies developed to combat cancer** Heba M. Hesham, Deena S. Lasheen, Khaled A.M. Abouzid *Med Res Rev*: 38:2058–2109 (2018) **Impact Factor ISI 8.75**. DOI: [10.1002/med.21505](https://doi.org/10.1002/med.21505)

- 105. Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma** Mai I. Shahin, Joyeeta Roy, Maha Hanafi, Dongyao Wang, Urarika Luesakul, Yifeng Chai, Nongnuj Muangsin, Deena S. Lasheen, Dalal A. Abou El Ella, Khaled A. Abouzid and Nouri Neamati *European Journal of Medicinal Chemistry* 29 May, 155: 516-530 (2018) (2018) <https://doi.org/10.1016/j.ejmech.2018.05.042> Impact Factor ISI: 4.86
- 106. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors** Sandra N. Milik, Amal Kamal Abdel-Aziz, Deena S. Lasheen, Rabah A.T. Serya, Saverio Minucci and Khaled A.M. Abouzid, *European Journal of Medicinal Chemistry* 155: 316-336 (2018). IF: 4.50 <https://doi.org/10.1016/j.ejmech.2018.06.011> Impact Factor ISI: 4.86
- 107. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, biological evaluation and molecular modeling**, Mai Adel, Rabah A. T. Serya, Deena S. Lasheen, Khaled A. M. Abouzid *Bioorganic Chemistry*, 81, 2018, 612-629. <https://doi.org/10.1016/j.bioorg.2018.09.001> IF 3.9
- 108. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidine scaffold as cancer targeting agents: Amna Ghith, Khairia M. Youssef, Khaled A. M. Abouzid.** *Bioorganic Chemistry*, 83, 2019, 111-128 <https://doi.org/10.1016/j.bioorg.2018.10.008> IF 3.9
- 109. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis** Bing-Hua Jiang, Xin Ge, Ming-Hong Pan, Lin Wang, Wei Li, Cheng-Fei Jiang, Jun He, Khaled Abouzid, *Cell Death and Disease* (2018) 9:1128, DOI 10.1038/s41419-018-1176-7 IF: 5.6
- 110. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.** Nevine M.Y. Elsayed¹, Dalal A. Abou El Ella, Rabah A.T. Serya, Mai F. Tolba, Marawan Ahmed, Khaled Barakat and Khaled A. M. Abouzid *Bioorganic Chemistry* Volume 82, February 2019, Pages 340-359 <https://doi.org/10.1016/j.bioorg.2018.10.071> IF 3.9
- 111. 3D-QSAR Pharmacophore Modelling, Virtual Screening and Docking Studies for Lead Discovery of a Novel Scaffold for VEGFR 2 Inhibitors: Design, Synthesis and Biological Evaluation** Mahitab K Sobhy, Samar Mowafy, Deena S Lasheen, Nahla A Farag, Khaled AM Abouzid *Bioorganic Chemistry* 89, 2019, 102988 <https://doi.org/10.1016/j.bioorg.2019.102988> IF 3.9
- 112. Design and Synthesis of New Quinoxaline Derivatives as Anticancer Agents and Apoptotic Inducers** Aliya El Newahie, Yassin M Nissan, Nasser SM Ismail, Abou El Ella, A Dalal, Sohair M Khojah, Khaled AM Abouzid, *Molecules* 24(6), 1175 2019; <https://doi.org/10.3390/molecules24061175>
- 113. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition**, Salwa Elmeligie, Asmaa M. Aboul-Magd, Deena S. Lasheen, Tamer M. Ibrahim, Tamer M. Abdelghany, Sohair M. Khojah & Khaled A. M. Abouzid, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 34:1, 1347-1367, 2019 DOI: 10.1080/14756366.2019.1642883.

- 114.** Identification of novel pyrazole and benzimidazole based derivatives as PBP2a inhibitors: Design, synthesis, and biological evaluation Menna-Allah W. Shalaby, Eman M. E. Dokla, Rabah A. T. Serya, Khaled A. M. Abouzid Archives of Pharmaceutical Sciences Ain Shams University 2019; Vol. 3(2):228-245 [DOI: 10.21608/APS.2019.16625.1010](https://doi.org/10.21608/APS.2019.16625.1010)
- 115.** **1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC** Eman M. E. Dokla, Chun-Sheng Fang, Khaled A. M. Abouzid, Ching S. Chen European Journal of Medicinal Chemistry 182, 11607, 2019
- 116.** Towards Discovery of Novel Scaffold with Potent Antiangiogenic Activity; Design, Synthesis of Pyridazine based Compounds, Impact of Hinge Interaction and Accessibility of their Bioactive Conformation on VEGFR-2 Activities Maiy Y. Jaballah, Rabah A.T. Serya, Nasser Saad, Sohair M. Khojah, Marawan Ahmed, Khaled Barakat and Khaled A. M. Abouzid, Journal of Enzyme Inhibition and Medicinal Chemistry **34:1, 1573-1589, 2019**
- 117.** Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors, Khulood H. Oudah, Mazin A. A. Najm, Nermin Samir, Rabah A. T. Serya and Khaled A. M. Abouzid, Bioorganic Chemistry **92, (31)103239, 2019.** <https://doi.org/10.1016/j.bioorg.2019.103239>
- 118.** **Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer,** Fatma M. Elmenier, Deena S. Lasheen and Khaled A. M. Abouzid, European Journal of Medicinal Chemistry Volume 183, 1 December 2019, 111718
<https://doi.org/10.1016/j.ejmech.2019.111718>
- 119.** **Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria,** Eman M.E. Dokla, Nader S. Abutaleb, Sandra N. Milika, DaoyiLib Karim El-Baz , Menna-Allah W. Shalaby , Rawan Al-Karakif Maha Nasr, Christian D.Klein, Khaled A.M. Abouzid Mohamed N.Seleem, European Journal of Medicinal Chemistry , [Volume 186](https://doi.org/10.1016/j.ejmech.2019.111850), 15 January 2020, 111850
<https://doi.org/10.1016/j.ejmech.2019.111850>
- 120.** **Identification of novel pyrazole and benzimidazole based derivatives as PBP2a inhibitors: Design, synthesis, and biological evaluation:** Menna-Allah W. Shalaby, Eman M.E. Dokla, Rabah A. T. Serya, Khaled A. M. Abouzid, Archives of Pharmaceutical Sciences Ain Shams University 2019; Vol. 3(2):142-159
[DOI: 10.21608/APS.2019.16625.1010](https://doi.org/10.21608/APS.2019.16625.1010)
- 121.** Acrylamide moiety, a Valuable Fragment in Medicinal Chemistry: Insight into Synthetic Methodologies, Chemical Reactivity and Spectrum of Biological Activities of Acrylamide Derivatives Hossam Elgiushy, Sherif Hammad, Ashraf Hassan Nageh Aboutaleb , Khaled Abouzid, Journal of advanced pharmacy research. Volume 2, Issue 4, 2018, 221-237 [DOI: 10.21608/aprh.2018.2839.1049](https://doi.org/10.21608/aprh.2018.2839.1049)

122. Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs, Mohamed H. Attia, Eman Z. Elrazaz, Soad Z. El-Emam, Azza Taher, Hatem A. Abdel-Aziz and Khaled A.M. Abouzid *Bioorganic Chemistry* [Volume 94](https://doi.org/10.1016/j.bioorg.2019.103517), January 2020, 103458 <https://doi.org/10.1016/j.bioorg.2019.103517>
123. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines, Mohamed S.H. Salem, Yasmine M. Abdel Aziz, Mohamed S. Elgawish, Mohamed M. Said and Khaled A.M. Abouzid, *Bioorganic Chemistry*, [Volume 94](https://doi.org/10.1016/j.bioorg.2019.103472), January 2020, 103472 <https://doi.org/10.1016/j.bioorg.2019.103472>
124. Synthesis and Antimicrobial Evaluation of New Halogenated 1,3-Thiazolidin-4-ones, Shaymaa G. Hammada, Marwa G. El-Gazzar, Nader S. Abutaleb, Daoy Li, Isabella Ramming, Aditya Shekhar, Mohammad Abdel-Halim, Eman Z. Elrazaz, Mohamed N. Seleem, Ursula Bilitewski, Khaled A.M. Abouzid, Ebaa M. El-Hossary *Bioorganic Chemistry*, [Volume 95](https://doi.org/10.1016/j.bioorg.2019.103517), January 2020, 103517. <https://doi.org/10.1016/j.bioorg.2019.103517>
125. Penicillin binding protein 2a: An overview and a medicinal chemistry perspective, Menna-Allah W. Shalaby, Eman M.E. Dokla, Rabah A.T. Serya, Khaled A.M. Abouzid *European Journal of Medicinal Chemistry* Available online 18 April (2020) <https://doi.org/10.1016/j.ejmech.2020.112312>
126. Targeting YAP Degradation by a Novel 1,2,4-Oxadiazole Derivative via Restoration of the Function of the Hippo Pathway, Eman M. E. Dokla, Chun-Sheng Fang, Po-Chen Chu, Chih-Shiang Chang, Khaled A. M. Abouzid, Ching S. Chen, *ACS Medicinal Chemistry Letters* 2020, 11, 4, 426-432 (Letter) [DOI: 10.1021/acsmc.2020.000501](https://doi.org/10.1021/acsmc.2020.000501)
127. Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors, Soha R. Abd El Hadi, Deena S. Lasheen, Dalia H. Soliman, Eman Z. Elrazaz, Khaled A. M. Abouzid *Bioorganic Chemistry*, 2020, [Volume 101](https://doi.org/10.1016/j.bioorg.2020.103961) 103961, 103517. <https://doi.org/10.1016/j.bioorg.2020.103961>
128. An investigative study of antitumor properties of a novel thiazolo[4,5-d]pyrimidine small molecule revealing superior antitumor activity with CDK1 selectivity and potent pro-apoptotic properties, Sameh H. Mohamed, Hossam R. Elgiushy, Heba Taha, Sherif F. Hammad, Nageh A. Abou-Taleb, Khaled A. M. Abouzid, Hussein Sawaf, Zeinab Hassan, *Bioorganic & Medicinal Chemistry* Volume 28, Issue 17, 1 September 2020, 115633. <https://doi.org/10.1016/j.bmc.2020.115633>
129. Design, Synthesis, and Biological Evaluation of Novel 7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine Inhibitors as Antitumor Agents, Muhammad I. Ismail, Samy Mohamady, Nermin Samir, and Khaled A. M. Abouzid, *ACS Omega* online 5 Aug, 2020 <https://doi.org/10.1021/acsomega.0c01829>
130. Design, Synthesis and In Silico Studies of New Quinazolinone Derivatives as Antitumor PARP-1 Inhibitors, Sayed K. Ramadan, Eman Z. Elrazaz, Khaled A. M. Abouzid and Abeer M. El-Naggar. *RSC Advances*, 2020, **10**, 29475 – 29492 [DOI: 10.1039/d0ra05943a](https://doi.org/10.1039/d0ra05943a)

- 131.** Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine based urea derivative with potential antitumor activity against Tamoxifen sensitive and resistant breast cancer cell lines, Marwa Sharaky, Marwa Kamel, Marwa A. Aziz, Mervat Omran, Monira M. Rageh, Khaled A. M. Abouzid, Samia A. Shouman, *Journal of Enzyme Inhibition and Medicinal Chemistry*, accepted on 24 July 2020, <https://doi.org/10.1080/14756366.2020.1804383>
- 132.** Elaborating piperazinyl-fuopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3K α) inhibitors to combat pancreatic cancer, Mai A. Mansour, Deena S. Lasheen, Hatem M. Gaber and Khaled A. M. Abouzid, *RSC Adv.*, 2020, 10, 32103, [DOI: 10.1039/d0ra06428a](https://doi.org/10.1039/d0ra06428a) [rsc.li](https://www.rsc.li)
- 133.** Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors, AM El-Araby, OM Qassem, EA El-Sawy, EZ El-Razaz, K Abouzid, ...*Egyptian Journal of Chemistry*, 64, 1575-1582, 2021
- 134.** Facile one-pot synthesis of thiazol-2 (3H)-imine derivatives from α -active methylene ketones., El-Sawah, Dalia E; Loksha, Yasser; Elrazaz, Eman; Abboud, Khalil A; Webster, Bradley Russell; Abouzid, Khaled AM; *Egyptian Journal of Chemistry*, 64, 1575-1582, 2021
- 135.** Structure-and ligand-based in silico studies towards the repurposing of marine bioactive compounds to target sars-cov-2, Fayed, Marwa AA; El-Behairy, Mohammed Farrag; Abdallah, Inas A; Abdel-Bar, Hend Mohamed; Elimam, Hanan; Mostafa, Ahmed; Moatasim, Yassmin; Abouzid, Khaled AM; Elshaier, Yaseen AMM; *Arabian Journal of Chemistry*, 14, 103092, 2021
- 136.** Antimicrobial and Cytotoxicity Evaluation of New 3-Allyl-2-iminothiazolidin-4-ones, Hammad, Shaymaa G; El-Gazzar, Marwa G; Abdel-Halim, Mohammad; Elrazaz, Eman Z; El-Hossary, Ebaa M; Abouzid, Khaled AM; *Egyptian Journal of Chemistry*, 64 (9), 4919-4930, 2021
- 137.** Discovery of Potent Thieno [2, 3-d] pyrimidine VEGFR-2 Inhibitors: Design, Synthesis and Enzyme Inhibitory Evaluation Supported by Molecular Dynamics Simulations, Elrazaz, Eman Z; Serya, Rabah AT; Ismail, Nasser SM; Albohy, Amgad; Abou El Ella, Dalal A; Abouzid, Khaled AM; *Bioorganic Chemistry* [Volume 113](https://doi.org/10.1016/j.bioorg.2021.105019), August 2021, 105019
<https://doi.org/10.1016/j.bioorg.2021.105019>
- 138.** Synthesis, in vitro biological investigation, and molecular dynamics simulations of thiazolopyrimidine based compounds as corticotrophin releasing factor receptor-1 antagonists, Elgiushy, Hossam R; Abou-Taleb, Nageh A; Holz, George G; Chepurny, Oleg G; Pirmettis, Ioannis; Kakabakos, Sotirios; Karageorgos, Vlasios; Liapakis, George; Albohy, Amgad; Abouzid, Khaled AM; *Bioorganic Chemistry*, [Volume 114](https://doi.org/10.1016/j.bioorg.2021.105079), September, 105079. 2021
<https://doi.org/10.1016/j.bioorg.2021.105079>

- 139.** Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer, Abdel-Atty, Mona M; Farag, Nahla A; Serya, Rabah AT; Abouzid, Khaled AM; Mowafy, Samar; *Journal of Enzyme Inhibition and Medicinal Chemistry*, 1, 361290-1312, 2021
- 140.** Synthesis, In Silico and In Vitro Antimicrobial Evaluation of Cyanoketene S, N-Acetals and their Pyrazoles Against Staphylococcus aureus DNA Gyrase Enzyme. Ali, Shima Mahmoud; HI Faraag, Ahmed; Elgiushy, Hossam; Said, Taghred; Askar, Ahmed; Hassan, Ashraf; Abouzid, Khaled; Fouad, Sherif; *Journal of Advanced Pharmacy Research*, 5, 341-361. 2021
- 141.** lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies, Hend Mohamed Abdel-Bar, Inas A. Abdallah, Marwa A. A. Fayed, Yassmin Moatasim, Ahmed Mostafa, Mohammed Farrag El-Behairy, Hanan Elimam, Yaseen A. M. M. Elshaier and Khaled A. M. Abouzid.; *RSC Adv.*, 11, 28876–28891, 2021
- 142.** Indolin-2-one Derivatives as Selective Aurora B Kinase Inhibitors Targeting Breast Cancer, Eman M. E. Dokla, Amal Kamal Abdel-Aziz, Sandra N. Milika. Amr H. Mahmoud Mona Kamal Saadeldin Martin J. McPhillied, Saverio Minucci. Khaled A.M. Abouzid. *Bioorganic Chemistry*, Available online 24 October 2021, 105451. <https://doi.org/10.1016/j.bioorg.2021.105451>
- 143.** Medicinal Chemistry Strategies Towards SO₂ Donors as Research Tools and Potential Therapeutics, [Eman M. El-labbad](#), [Xingyue Ji](#), [Khaled A.M. Abouzid](#), [Binghe Wang](#), , *Current Topics in Medicinal Chemistry*, 2021, 21, 2870-2881
[10.2174/1568026621666211116091354](https://doi.org/10.2174/1568026621666211116091354)
- 144.** Design, Synthesis and Biological Evaluation of New Thieno[2,3-d]pyrimidine Derivatives as Targeted therapy for PI3K with Molecular Modelling Study. FM Elmenier, DS Lasheen, KAM Abouzid, *Journal of Enzyme Inhibition and Medicinal Chemistry* 37 (1), 315-332
- 145.** Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity, Eman M. Awad, Cyrielle Billon, Bahaa Elgendy, Khaled A.M. Abouzid, Shaymaa E. Kassab. *Bioorganic Chemistry* [Volume 119](#), February 2022, 105554
- 146.** Discovery of a Benzimidazole-based Dual FLT3/TrKA Inhibitor Targeting Acute Myeloid Leukemia, Eman ME Dokla, Amal Kamal Abdel-Aziz, Sandra N Milik, Martin J McPhillie, Saverio Minucci, Khaled AM Abouzid, *Bioorganic & Medicinal Chemistry*, [Volume 56](#), 15 February 2022, 116596
- 147.** Identification of a promising hit from a new series of pyrazolo[1,5-*a*]pyrimidine based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep *in vitro* assessment, Hossam R. Elgiushy, Sameh H. Mohamed, Heba Taha, Hussein Sawaf, Zeinab Hassan, Nageh A. Abou-Taleb, Eman M. El-labbad, Ashraf S. Hassan, Khaled A. M. Abouzid, Sherif F. Hammad

- 148.** Identification of novel furo[2,3-d]pyrimidine based chalcones as potent anti-breast cancer agents: synthesis, in vitro and in vivo biological evaluation† Mai A. Mansour, Mamdouh A. Oraby, Zeinab A. Muhammad, Deena S. Lasheen, Hatem M. Gaber and **Khaled A. M. Abouzi** RSC Adv., **2022**, 12, 8193, DOI: 10.1039/d2ra00889k
- 149.** Insights into the design of inhibitors of the EGFR family with anticancer activity overcoming resistance: A case of optimizing thieno[2,3-d]pyrimidine-based EGFR inhibitors Sandra N. Milik, Amal Kamal Abdel-Aziz Morad M. El-Hendawy Riham I. El-Gogary Mona Kamal Saadeldin . Saverio Minucci. , **Khaled A.M. Abouzi**, Journal of Molecular Structure. 1259, 5 2022, 132724, <https://doi.org/10.1016/j.molstruc.2022.132724>
- 150.** Tackling Microbial Resistance with Isatin-Decorated Thiazole Derivatives: Design, Synthesis, and in vitro Evaluation of Antimicrobial and Antibiofilm Activity RM Kassab, SA Al-Hussain, NS Elleboudy, A Albohy, MEA Zaki, Drug Design, Development and Therapy 16, 2817-2832 (2022)
- 151.** Towards Selective Binding to the GLUT5 Transporter: Synthesis, Molecular Dynamics and In Vitro Evaluation of Novel C-3-Modified 2,5-Anhydro-D-mannitol Analogs, N Rana, MA Aziz, AK Oraby, M Wuest, J Dufour, KAM Abouzi, F Wuest, ...Pharmaceutics 14 (4), 828 (2022)
- 152.** New fluorinated diarylureas linked to pyrrolo [2,3-d] pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation, M Adel, KAM Abouzi, Bioorganic Chemistry 127, 106006 (2022)

Patents

- 1- Novel Curcumin analogs with anticancer activity
PCT/EG2013/000028 appl date 17/11/2013 International Application No.: 14.05.2015 , WO/2015/067282.
- 2- New Targeted Therapy For Cancer Treatment. Samar Mohamed Ahmed Mowafy and Khaled Abouzi Mohamed Abouzi 1371/2012, appl date 29/7/2012 Patent office Scientific Research Academy, Cairo , Egypt
- 3- Novel targeted anticancer therapeutics, Yasmine Mohamed, Khaled Abouzi et al 1468/2014, appl 17/9/2014 Patent office Scientific Research Academy, Cairo , Egypt.
- 4- Small molecules targeting tyrosine kinase and anticancer agents, Khaled Abouzi, Rabah T Serya, Deena Lasheen and Marwa AbdelAziz 1503/2014, appl date: 23-9-2014
- 5- Small molecules targeting VEGFR tyrosine kinase as anticancer agents, Dalal Abouellella, Khaled Abouzi, Rabah T Serya, and Nivene Mohamed 2107/2014 appl date: 30-12-2014

- 6- Small molecules targeting tyrosine kinase and anticancer agents, Khaled Abouzid, Salwa Elsaïd Elmeligy, Deena Lasheen and Asmaa M Aboulmagd 133/2015, appl date: 26-1-2015
- 7- Pyridazine compounds as tyrosine kinase inhibitors and anticancer agents, Khaled Abouzid, Mai Yousef and Rabah T Serya 546/2017, appl date: 28-3-2017
- 8- Thienopyrimidine compounds as tyrosine kinase inhibitors and anticancer agents Khaled Abouzid, Eman Zaglol El-Razaz and Rabah T Serya 545/2017, appl date: 28-3-2017
- 9- Furopyrimidine compounds as EGFR/Her2 as anticancer agents Khaled Abouzid, Monia Hossam and Deena Lasheen 547/2017, appl date: 28-3-2017
- 10- Thieno[2,3-d]pyrimidines as EGFR/Her2 dual inhibitors for cancer therapy Khaled Abouzid, Sandra Milik, Deena Lasheen and Rabah Taha 2181/2017, appl date: 26-12-2017
- 11- Pyrrolo[2,3-d]pyrimidines as VEGFR-2 inhibitors for cancer therapy Khaled Abouzid, Mai Adel, Deena Lasheen and Rabah Taha 2182/2017, appl date: 26-12-2017

List of Conferences ,

1. XX Conference of Pharmaceutical Sciences, Dar El Hekma, Cairo, Feb. (1988).
2. Eighteenth New England Regional Medicinal Chemistry and Pharmacognosy Meeting NERMACAP XVIII, Northeastern University, Boston, Massachusetts, USA May (1993).
3. Nineteenth New England Regional Medicinal Chemistry and Pharmacognosy Meeting NERMACAP XXIX, St. John's University, Jamaica, New York, USA April (1994).
4. XXIV Conference of Pharmaceutical Sciences, Cairo International Conference Center, Dec. (1994).
5. 7th IBN SINA International Conference on pure and Applied Heterocyclic Chemistry. El Montazaa Sheraton, Alexandria, March 25-28 (2000).
6. XXVII Conference of Pharmaceutical Sciences, Cairo Meridian Hotel Cairo, Jan 2-4. (2001).
7. Assiut University Third Pharmaceutical Sciences Conference. Assiut, Egypt, March 5-6, (2002).
8. International Meeting on Medicinal and Pharmaceutical Chemistry IMMPC-1, Ankara- Turkey, Sept 25-28 (2002)
9. Azhar 3rd International Conference for Pharmaceutical and Biological Sciences December 16-18, 2003.
10. 9th IBN SINA International Conference on Pure and Applied Heterocyclic Chemistry. Sharm El-Sheikh, December 11-14 (2004).

11. Mini Symposium in Medicinal Chemistry at the Faculty of Biology and Pharmacy, Friedrich-Schiller-Universität Jena, Germany. September 2005.
12. 5th Pharmaceutical Sciences Conference, Assiut University. Assiut, Egypt, March 7-8, (2006).
13. Dubai International Pharmaceuticals and Technologies Conferences and Exhibition (DUPHAT) 20-22 March 2007
14. 1st Scientific Conference of Faculty of Pharmacy, Cairo University, March 29th, 2008.
15. 11th Ibn Sina International Conference on Pure & Applied Heterocyclic Chemistry, Triumph Hotel, Cairo 16th December, 2008.
16. 3rd International Conference on Drug Discovery & Therapy Feb 7-10, 2011 Dubai, UAE.
17. 4th EuCheMS Chemistry Congress, Prague, Czech Republic 26-30 August 2012. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents (oral presentation).
18. 13th Tetrahedron Symposium, Challenges in Bioorganic & Organic Medicinal Chemistry, 26-29 June 2012 Amsterdam, The Netherlands.
19. 73th international congress of FIP (World congress of pharmacy and pharmaceutical sciences) held from 31 Aug to 5 Sept 2013 in Dublin, Ireland. Modeling and synthesis of novel curcumin analogs with anticipated anticancer activity.
20. 14th Tetrahedron Symposium, Asia Edition (Challenges in Organic and Bioorganic Chemistry), Seoul Korea, (Structure-based design and synthesis of novel kinase inhibitors based on pseudosaccharine scaffold as potential antiproliferative agents). 21-24 October 2013
21. The first international conference, Faculty of pharmacy, Ain Shams 2014 an invited speaker
22. 16th Tetrahedron Symposium Asia Edition, Shanghai, China 'Discovery of potent anti-proliferative agents targeting EGFR tyrosine kinase based on pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine scaffold' 10-13 November 2015
23. Ain Shams 'university conference 2016 as a speaker
24. ICPS2017, Future university conference, Cairo Egypt, molecular design and synthesis of sorafenib analogues as VEGFR2 and Angiogenesis inhibitors 2017
25. AIPC conference speaker and vice president of the conference Discovery of Mutant EGFR/HER-2 Dual Inhibitors as Potent

Anticancer Drug Candidates March 2017, Intercontinental Hotel, City Stars Cairo Egypt.

26. ZCEBS Zewail City Conference Biomedical Sciences Toward discovery of novel anti-angiogenic small molecules targeting VEGFR-2 as potential anti-cancer agents speaker 21-22 April 2017
27. Breast-Gynecological and immunooncology international cancer conference BGICCC 18-19 Jan 2018 Hilton towers Hotel, Cairo Egypt as speaker Toward discovery of small organic molecules as potent VEGF-2 inhibitors
28. Second AIPC conference speaker (Shaping Pharma's Future) 17-18 March 2019, Hilton towers Hotel, Cairo Egypt. As conference president
29. Faculty of Pharmacy, Nahda University conference. Invited speaker, lecture titled toward discovery of small organic molecules as potent VEGF-2 inhibitors 6-7 March 2018
30. 9th International Scientific Conference of Faculty of Pharmacy Cairo University Main Library 25-26 April 2018. Invited speaker Towards Discovery of Novel Anticancer Analogues Targeting Vascular Endothelial Growth Factor Receptor (VEGFR): Current status and future directions
31. **2nd International Scientific Conference of the Faculty of Pharmacy, Ain Shams University (CPASU) Novotel hotel airport as invited speaker Discovery of Potent Small Organic Molecules Targeting VEGFR-2 through Computational Drug Design on 13-15 Nov 2018**
32. **Breast-Gynecological and immunooncology international cancer conference BGICCC 17-18 Jan 2019 Hilton towers Hotel, Cairo Egypt as speaker** Towards discovery of potential targeted drug candidates for cancer therapy 2019
33. **Future conference** Toward discovery of potent kinase inhibitors as targeted anti-cancer drug candidates Invited speaker **2019**
34. **Breast-Gynecological and immunooncology international cancer conference BGICCC 16-17 Jan 2020 Hilton towers Hotel, Cairo Egypt as speaker** Towards discovery of potential targeted drug candidates for cancer therapy 2020
35. Faculty of Pharmacy, Nahda University conference. Invited speaker, 1-2 March 2022